(102) examined PD-L1 expression in 76 LCNEC patients, revealing that only 22% patients were positive for PD-L1 and, that positivity, was found on the tumor cell surface in 22% and within the tumor microenvironment (immune-cell infiltrate) in 36% of the patients. The gene discussed is CD274; the disease is large cell neuroendocrine carcinoma.